Derzeitiger Stand der Immuntherapie des fortgeschrittenen Nierenzellkarzinoms

  • G. G. Steger
  • T. Duckett
  • A. Belldegrun
Conference paper

Zusammenfassung

Durch die Fortschritte in der Immunologie und Biotechnologie der letzten Jahre konnten neue und vielversprechende Strategien für die Immuntherapie maligner Erkrankungen entwickelt werden. Zytokine wie Interferone und Interleukine entfalten neben gewissen zytotoxischen Eigenschaften hauptsächlich aktive und passive immunologische Aktivität im Tumorträger. Die sog. „adoptive Immuntherapie“besteht aus 2 Hauptkomponenten: einer großen Anzahl (1 × 109 – 5 × 1011) immunkompetenter lymphoider Zellen mit hoher Antitumorreaktivität und rekombinante Zytokine für immunologische Manipulationen in vitro und in vivo. In der Vergangenheit waren die Therapie mit Zytokinen und die Ex-vivo-Herstellung von effektiven Antitu-morzellen von der Verfügbarkeit genügend großer Mengen dieser Zytokine in entsprechendem Reinheitsgrad abhängig. Durch die Entwicklung molekularbiologischer Methoden können diese Substanzen nun aber in praktisch unbeschränkter Menge in rekombinanter Form hergestellt werden, wodurch der experimentellen und auch der klinischen Forschung diesbezüglich keine Grenze mehr gesetzt ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Asher AL, Mule JJ, Kasid A et al. (1991) Murine tumor oelle transduced with the gene for tumor nacrosis factor-a: avidence for paracrine immune effects of tumor nacrosis factor against tumors. J Immunol 146: 3227–3234PubMedGoogle Scholar
  2. Balkwill FR, Moodie EM (1984) Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 44: 904–910PubMedGoogle Scholar
  3. Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48: 206–214PubMedGoogle Scholar
  4. Belldegrun A, Tso CL, Sakata T, Brunda M, deKernion JB (1992) Characterization and function of human renal cancer lines genetically engineered to produce IL-2 and/or IFN-aplha. Proc Am Assoc Cancer Res 33: 331 (Abstr 1976)Google Scholar
  5. Blankenstein T, Qin ZH, Uberla K, Muller W, Rosen H, Volk HHD, Diamantstein T (1991) Tumor suppression after tumor cell-rageted tumor necrosis factor alpha gene transfer. J Exp Med 173: 1047–1052PubMedCrossRefGoogle Scholar
  6. Bukowaki RM, Sharfman W, Murthy S et al. (1991) Clinical results and characterization of tumor-infiltrating lymphocytes with or withour recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Res 51: 4199–4205Google Scholar
  7. Carmichael J, Fergusson RJ, Wolf CR, Balkwill FR, Smyth JF (1986) Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts. Cancer Res 46: 4916-PubMedGoogle Scholar
  8. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G (1991) Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173: 889–897PubMedCrossRefGoogle Scholar
  9. Creagan ET, Bukcner JC, Hahn RG (1988) An evaluation of recombinant leukocyte A interferon with aspirin in patients with metastatic renal cell cancer. Cancer 61: 1787–1791PubMedCrossRefGoogle Scholar
  10. Creagan ET, Twito DI, Johansson SL et al. (1991) A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 9: 2104–2109PubMedGoogle Scholar
  11. Fearon ER, Pardoll DM, Itaya T et al. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397–403PubMedCrossRefGoogle Scholar
  12. Figlin RA, Belldegrun A, Modawer N, Zeffran J, deKernion JB (1992a) Concomitant administration recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10: 414–421PubMedGoogle Scholar
  13. Figlin RA, Belldegrun A, deKernion JB (1992b) Immunotherapy of patients with metastatic renal cell carcinoma (RCCa) using an outpatient regimen of interleukin-2 (IL-2) and interferon-alpha (IFN) administered either alone or with in vivo primed tumor infiltrating lymphocytes (pTIL): The UCLA experience. Proc Am Soc Clin Onocol 11: 197 (Abstr 603)Google Scholar
  14. Finke JH, Ryman P, Alexander J et al. (1990) Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res 50: 2363–2370PubMedGoogle Scholar
  15. Finke JH, Rayman P, Edinger M, Tubbe RR, Stanley J, Klein E, Bukowski RM (1992) Characterization of a human renal cell oarcinoma specific cytotoxic CD8+ Tcell line. J Immunother 11: 1–11PubMedCrossRefGoogle Scholar
  16. Fisher RI, Coltman CA, Doroshow JG et al. (1988) Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: a phase II clinical trial. Ann Intern Med 108: 518–523PubMedGoogle Scholar
  17. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990a) Retroviral vector-mediated g-inferferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50: 7820–7825PubMedGoogle Scholar
  18. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990b) Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217–1224PubMedCrossRefGoogle Scholar
  19. Gautman SC, Chikkala NF, Ganapathi R, Hamilton RA (1991) Combination therapy with adriamycin and interleukin-2 augments immunity against murine renal cell carcinoma. Cancer Res 51: 6133–6137Google Scholar
  20. Geertsen PF, Hermann GG, von der Maase H, Steven K (1992) Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study. J Clin Oncol 10: 753–759PubMedGoogle Scholar
  21. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffes LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713–716PubMedCrossRefGoogle Scholar
  22. Hayakawa K, Salmeron MA, Parkinson DR et al. (1991) Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotxicT cells in RCC. J Immunother 10: 313–325PubMedCrossRefGoogle Scholar
  23. Hock H, Dorsch M, Diamantstein T, Blankenstein T (1991) Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 174: 1291–1298PubMedCrossRefGoogle Scholar
  24. Kim TY, von Eschenbach AC, Filaccio MD, Hayakawa K, Parkinson DR, Balch CM, Itoh K (1990) Clonal analysis of lymphocytes from tumor, peripheral blood and nontumorous kdney in primary renal cell carcinoma. Cancer Res 50: 5263–5268PubMedGoogle Scholar
  25. Koo AS, Tso CL, Shimabukuro T, Peyret C, deKernion JB, Belldegrun A (1991) Autologous tumor-specific oytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 10: 347–354PubMedCrossRefGoogle Scholar
  26. Koretz MJ, Lawson DH, York RM et al. (1991) Randomized study of interleukin-2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer. Arch Surg 126: 698–903Google Scholar
  27. von der Maase H, Geertsen P, Thatcher N et al. (1991) Recombinant interleukin-2 in metastatic renal cell carcinoma: a european multicentre phase II study. Eur J Cancer 27: 1583–1589PubMedCrossRefGoogle Scholar
  28. Marumo K, Ueno M, Muraki J et al. (1991) Antitumor effects of interleukin-2 against renal cell carcinoma: basic study and clinical application. Urol Int 47 (Suppl 1): 132–137PubMedCrossRefGoogle Scholar
  29. Mittelmann A, Puccio C, Ahmed T, Zeffren J, Choudhury A, Arlin Z (1991) Trial of interleukin-2 by continuous infusion and interferon by intramuscular injection in patients with renal cell carcinoma. Cancer 68: 1699–1702CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • G. G. Steger
  • T. Duckett
  • A. Belldegrun

There are no affiliations available

Personalised recommendations